 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234567» |
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Efficacy, safety and implementation outcomes of Cabotegravir + Rilpivirine long-acting by country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_627;
High and comparable acceptability, appropriateness, and feasibility of CAB+RPV LA was seen across different countries. These data support CAB+RPV LA as a complete regimen for the maintenance of virologic suppression in PLWH in diverse European healthcare settings.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir + Rilpivirine long-acting efficacy and safety outcomes by sex at birth, age and race: a subgroup analysis of the CARISEL study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_626;
P3
These data support CAB+RPV LA as a complete regimen for the maintenance of virologic suppression in PLWH in diverse European healthcare settings. Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir + Rilpivirine long-acting efficacy and safety outcomes by sex at birth, age and race: a subgroup analysis of the CARISEL study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_625;
P3
Conclusions : Conclusions :
- Rekambys (rilpivirine LA) / J&J
HIV viremias among patients who discontinued Cabotegravir(CAB)/ Rilpivirine(RPV) Long acting(LA) intramuscular(IM) in real-life setting (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_574;
Conclusions : Purpose :
- Rekambys (rilpivirine LA) / J&J
HIV viremias among patients who discontinued Cabotegravir(CAB)/ Rilpivirine(RPV) Long acting(LA) intramuscular(IM) in real-life setting (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_573;
Purpose : Purpose :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Safety of cabotegravir/rilpivirine long acting for individuals previously exposed to HBV infection (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_568;
Linear regression analysis failed to predict a significant FIB-4 evolution over time within the overall (b=-0.004, CI: -0.183-0.175, p=0.967), the HBV-exposed (b=-0.081, 95% CI: -0.440-0.279, p=0.659), and the unexposed population (b=-0.000, 95% CI: -0.180-0.180, p=0.997) (Figure 2). Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Safety of cabotegravir/rilpivirine long acting for individuals previously exposed to HBV infection (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_567;
Linear regression analysis failed to predict a significant FIB-4 evolution over time within the overall (b=-0.004, CI: -0.183-0.175, p=0.967), the HBV-exposed (b=-0.081, 95% CI: -0.440-0.279, p=0.659), and the unexposed population (b=-0.000, 95% CI: -0.180-0.180, p=0.997) (Figure 2). Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Marginalization related to material deprivation and ethnic concentration among patients receiving injectable ART at academic HIV clinics in Toronto (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_564;
Conclusions : Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Marginalization related to material deprivation and ethnic concentration among patients receiving injectable ART at academic HIV clinics in Toronto (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_563;
Further efforts to ensure equitable access to CAB/RPV-LA are needed. Table 1: Demographics and HIV risk factors of included patients Figure 1: Distribution of included patients according to levels of marginalization
- Rekambys (rilpivirine LA) / J&J
Total HIV-DNA trend in complex ART-experienced PLWH switching to CAB+RPV long-acting injectable: 28-week results in a home-care assistance setting (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_544;
Table 1: Demographics and HIV risk factors of included patients Figure 1: Distribution of included patients according to levels of marginalization Conclusions :
- Rekambys (rilpivirine LA) / J&J
Total HIV-DNA trend in complex ART-experienced PLWH switching to CAB+RPV long-acting injectable: 28-week results in a home-care assistance setting (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_543;
Conclusions : Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
UK Multi-centre service evaluation of long-acting injectable CAB/RPV pathways (SHARE LAI-net) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_538;
Conclusions : Purpose :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
UK Multi-centre service evaluation of long-acting injectable CAB/RPV pathways (SHARE LAI-net) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_537;
Purpose : Purpose :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Durability and schedule compliance to cabotegravir/rilpivirine long acting: a retrospective analysis (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_520;
With binary regression analysis, the only factor significantly associated to delayed administration was a previous two-drugs regimen before switch (OR 0.32, 95% CI 0.129-0.792, p=0.014). Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Durability and schedule compliance to cabotegravir/rilpivirine long acting: a retrospective analysis (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_519;
With binary regression analysis, the only factor significantly associated to delayed administration was a previous two-drugs regimen before switch (OR 0.32, 95% CI 0.129-0.792, p=0.014). Conclusions :
- Vocabria (cabotegravir oral) / ViiV Healthcare
Real-world data on commercial long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results: findings from a University Hospital in Paris, France (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_510;
Conclusions : Purpose :
- Vocabria (cabotegravir oral) / ViiV Healthcare
Real-world data on commercial long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results: findings from a University Hospital in Paris, France (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_509;
Purpose : Purpose :
- Vocabria (cabotegravir oral) / ViiV Healthcare
Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_506;
Purpose : Purpose :
- Vocabria (cabotegravir oral) / ViiV Healthcare
Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_505;
Purpose : Purpose :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: efficacy and tolerance during the first 72 weeks (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_460;
Purpose : Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: efficacy and tolerance during the first 72 weeks (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_459;
Conclusions : Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_440;
Conclusions : Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_439;
Conclusions : Conclusions :
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy. (Pubmed Central) - Sep 23, 2023
All patients achieved viral suppression without any virologic rebound. iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy.
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date: Implementing Cabenuva in Arkansas HIV Programs (clinicaltrials.gov) - Sep 13, 2023
P=N/A, N=100, Recruiting, Sponsor: University of Arkansas
iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy. Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Oct 2024
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: results from the Dutch ATHENA national observational cohort (POLONEZ) - Sep 10, 2023 - Abstract #EACS2023EACS_294;
Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Oct 2024 Purpose :
- bictegravir (GS-9883) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi, Vemlidy (tenofovir alafenamide) / Gilead
Uptake and discontinuation of the long-acting duo in the Swiss HIV Cohort Study: preliminary analysis on cabotegravir plus rilpivirine (POLONEZ) - Sep 10, 2023 - Abstract #EACS2023EACS_293;
The vast majority of participants switched from an integrase strand transfer inhibitor-based regimen, with a high proportion having prior exposure to RPV. CAB+RPV-LA discontinuation and confirmed virological failure (0.4?????%) were low.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Failure following switch from long-term suppressive oral ART to long-acting cabotegravir/rilpivirine injections (POLONEZ) - Sep 10, 2023 - Abstract #EACS2023EACS_292;
CAB+RPV-LA discontinuation and confirmed virological failure (0.4?????%) were low. Conclusions :
- Vocabria (cabotegravir oral) / ViiV Healthcare, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir-rilpivirine long acting: data in real life setting in a large French cohort (ePosters area) - Sep 10, 2023 - Abstract #EACS2023EACS_263;
Treatment interruption for VR was rare (0.5%) and analysis of emerging resistance at VR is ongoing. A prolonged follow-up is needed to confirm long term efficacy and tolerability.
- Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2998;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2997;
- Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine Among People with HIV with Detectable Viral Loads at Initiation: Trio Cohort Study (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2982;
- Real-World Outcomes with Cabotegravir/Rilpivirine: Does Duration of Pre-treatment Viral Suppression Matter? (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2979;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Weight Change among People Living with HIV who switch from Oral Antiviral Therapy to Long Acting Injectable Cabotegravir/Rilpivirine in a University-Based Clinic (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2978;
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2977;
- The Annual Cost per Newly Virally-Suppressed Person with HIV in Those Starting Long-Acting Injectable Antiretroviral Therapy with Detectable Viremia in a Safety-Net Clinic in San Francisco (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2975;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2957;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2952;
- Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1355;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1354;
- Hepatitis B Reactivation in Persons with HIV with Positive Hepatitis B Core Antibody after Switching to Antiretroviral Therapy without Hepatitis B Activity (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1353;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real-world Adherence and Persistence with Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Compared to Oral Antiretroviral Therapy (ART) Among People with HIV (PWH) in the US: The ABOVE Study (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1351;
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use. (Pubmed Central) - Aug 16, 2023
The most common RPV-RAM in both groups was E138A. Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation in this setting.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial initiation date: Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (clinicaltrials.gov) - Aug 16, 2023
P1/2, N=90, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation in this setting. Initiation date: Jul 2023 --> Oct 2023
- | Edurant (rilpivirine) / J&J, Sublocade (buprenorphine once-monthly depot) / Indivior, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P1 trial, Adherence: CHOICE: Combined Injectable Treatment for HIV and OUD (clinicaltrials.gov) - Aug 14, 2023
P1, N=40, Recruiting, Sponsor: Rhode Island Hospital
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Immune Reconstitution Inflammatory Syndrome in Aids Patient After Successful Induction of Virological Suppression with Cabotegravir/Rilpivirine. (Pubmed Central) - Aug 9, 2023
CAB/RPV has no activity against HBV, which may have contributed to its reactivation.The patient had serologic evidence of resolution of prior HBV. However, some patients have covalently closed circular DNA (cccDNA) that may remain long term in hepatocyte nuclei.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Acceptability, Feasibility, and Appropriateness of Implementation of Long-acting Injectable Antiretrovirals: A National Survey of Ryan White Clinics in the United States. (Pubmed Central) - Jul 31, 2023
The approval of long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) heightened the urgency of ensuring effective implementation...There is variability of readiness yet high levels of perceived acceptability and appropriateness of implementing LAI CAB/RPV among Ryan White clinics, necessitating tailored interventions for successful implementation. A special focus on addressing the barriers of adherence and the cost of implementation is needed.
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 (Pubmed Central) - Jul 15, 2023
P3
A special focus on addressing the barriers of adherence and the cost of implementation is needed. From the Spanish National Health System perspective, CAB+RPV LA Q2M is a cost-effective alternative compared with the current options of daily oral STR regimens for HIV treatment.
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV. (Pubmed Central) - Jul 3, 2023
Further data on the ability of LA-ART to achieve viral suppression in people with barriers to adherence are needed. National Institutes of Health, City and County of San Francisco, and Health Resources and Services Administration.
- |||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
These findings offer reassurance that people with #HIV who start or switch to modern integrase inhibitor antiretroviral regimens, including Biktarvy or Cabenuva, can keep the virus under control for years. @PaulSaxMD @overton_edgar https://t.co/KLV9Pk9LpE (Twitter) - Jun 14, 2023